Human papilloma virus (HPV)
For women in the EU aged 15-44, cervical cancer is the second most common form after breast cancer. Cervical cancer is caused by certain strains of human papilloma virus (HPV). In different studies, HPV was detected in more than 90% of cervical cancers.
There are vaccines that can prevent infection with the types of HPV that most commonly cause cancer. Countries with cervical cancer screening programs have substantially reduced cervical cancer incidence and deaths.
EU authorisation – two HPV vaccines
Following the green light from the scientific committee of the European Medicines Agency, the EU authorised the marketing of two HPV vaccines that prevent infections with the two main strains of HPV that cause cervical cancer:
EU collaboration platform and expert group
EU countries exchange information on HPV immunisation, and other activities relating to HPV, using the VENICE (Vaccine European New Integrated Collaboration Effort) platform.
The European Commission acts as facilitator/coordinator. The European Centre for Disease Prevention and Control funds the platform and has set up an expert group to look into introducing HPV vaccination in EU countries.
HPV vaccines do not give 100% protection against cervical cancer and vaccination is not a replacement for routine cervical screening. National authorities are encouraged to carry out organised population-wide cervical screening by smear test before introducing HPV vaccination. This screening should take account of the European guidelines for quality assurance in cervical cancer screening and diagnosis.